922718-57-8

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-2-METHYL-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE
• Synonyms: 1,2,3,4-TETRAHYDRO-2-METHYL-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE;2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoqu;2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline;2-Methyl-1,2,3,4-tetrahydro-isoquinoline-6-boronic acid pinacol ester
• CAS NO: 922718-57-8
• Molecular Formula: C₁₆H₂₄BNO₂
• Molecular Weight: 273.19
• Mol File: 922718-57-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 370.5°C at 760 mmHg
• Flash Point: 177.9°C
• Appearance: /
• Density: 1.06g/cm³
• Vapor Pressure: 1.1E-05mmHg at 25°C
• Refractive Index: 1.532
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-2-METHYL-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-2-METHYL-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(922718-57-8)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-2-METHYL-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-ISOQUINOLINE(922718-57-8)

Safety Data

• Hazardous Substances Data: 922718-57-8(Hazardous Substances Data)

Usage

General Description

1,2,3,4-Tetrahydro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-isoquinoline is a chemical compound that belongs to the category of organic compounds known as isoquinolines. As an isoquinoline, it refers to a class of compounds containing an isoquinoline moiety, which is a bicyclic heterocycle made up of a benzene ring fused to a pyridine ring. Other fundamental characteristics include the presence of the tetramethyl-1,3,2-dioxaborolan-2-yl group which comprises boron in its structure and propound potential chemistry with boron, which may encompass diverse and significant biological activities. The existence and placement of a methyl group also contribute to its characteristic chemical behavior. The specific functional groups and structure suggest potential roles in pharmaceuticals or other chemical sectors, although specific uses aren't mentioned in the chemical's name.

InChI:InChI=1/C16H24BNO2/c1-15(2)16(3,4)20-17(19-15)14-7-6-13-11-18(5)9-8-12(13)10-14/h6-7,10H,8-9,11H2,1-5H3

Upstream product

• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 59961-00-1 6-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 73183-34-3 bis(pinacol)diborane 
• 14097-39-3 N-methyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 34784-05-9 6-bromo-isoquinoline 
• 675576-26-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinoline 
• 922718-56-7 2-methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinolinium; iodide 

Relevant articles and documents

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

PYRROLO[2,3-B]PYRIDINES AS HPK1 INHIBITOR AND USES THEREOF

Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.